Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.41 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17414151 | 0.83 | LPAR1 (0.50) | ALDH1A1MAPTMEN1KMT2AHTT | |
| SCHEMBL23099416 | 0.83 | BCHE (0.42) | SUV39H2KDM4D | |
| SCHEMBL21056153 | 0.82 | KDM4E (0.50) | ALDH1A1MAPTGAAHTTSUV39H2 | |
| SCHEMBL8052509 | 0.79 | PTPN11 (0.53) | ALDH1A1MAPTMEN1GAAKMT2A | |
| SCHEMBL30305200 | 0.79 | ABCB1 (0.43) | ALDH1A1GAAKDM4DPTPN11ABCB1 | |
| SCHEMBL23775495 | 0.79 | ABCB1 (0.43) | ALDH1A1GAAKDM4DPTPN11ABCB1 | |
| SCHEMBL658538 | 0.76 | ALDH1A1 (0.42) | ALDH1A1MAPTMEN1GAAKMT2A | |
| SCHEMBL17662315 | 0.76 | KMT2A (0.60) | ALDH1A1MAPTMEN1GAAKMT2A | |
| SCHEMBL658861 | 0.75 | ALDH1A1 (0.47) | ALDH1A1MAPTMEN1GAAKMT2A | |
| Trifluoroacetic Acid SCHEMBL660384 | 0.74 | CHIT1 (0.46) | ALDH1A1MAPTMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012022707-A1 | SUBSTITUTED HETEROARYL SPIROPYRROLIDINE MDM2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-23 | — | — | WO | disclosed |
| US-20120046306-A1 | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists | BARTKOVITZ DAVID JOSEPH (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046306-A1 | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists | MDM2, TP53, RB1 | ALDH1A1 1065/4885MAPT 3625/4885MEN1 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.